JP2011503162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503162A5 JP2011503162A5 JP2010533657A JP2010533657A JP2011503162A5 JP 2011503162 A5 JP2011503162 A5 JP 2011503162A5 JP 2010533657 A JP2010533657 A JP 2010533657A JP 2010533657 A JP2010533657 A JP 2010533657A JP 2011503162 A5 JP2011503162 A5 JP 2011503162A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- eye
- matrix metalloproteinase
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 26
- 210000001508 eye Anatomy 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 230000036573 scar formation Effects 0.000 claims description 8
- 238000002513 implantation Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 5
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 210000005252 bulbus oculi Anatomy 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 239000007892 solid unit dosage form Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229950003608 prinomastat Drugs 0.000 claims 2
- YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- JXAGDPXECXQWBC-LJQANCHMSA-N Tanomastat Chemical compound C([C@H](C(=O)O)CC(=O)C=1C=CC(=CC=1)C=1C=CC(Cl)=CC=1)SC1=CC=CC=C1 JXAGDPXECXQWBC-LJQANCHMSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229950001858 batimastat Drugs 0.000 claims 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960003696 ilomastat Drugs 0.000 claims 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 claims 1
- 229950008959 marimastat Drugs 0.000 claims 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 description 9
- 229940124761 MMP inhibitor Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0722484.3A GB0722484D0 (en) | 2007-11-15 | 2007-11-15 | Solid compositions |
| PCT/GB2008/003851 WO2009063222A2 (en) | 2007-11-15 | 2008-11-17 | Solid compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503162A JP2011503162A (ja) | 2011-01-27 |
| JP2011503162A5 true JP2011503162A5 (https=) | 2013-11-28 |
Family
ID=38896404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533657A Pending JP2011503162A (ja) | 2007-11-15 | 2008-11-17 | 固体組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100278896A1 (https=) |
| EP (1) | EP2219644A2 (https=) |
| JP (1) | JP2011503162A (https=) |
| CN (1) | CN102316854A (https=) |
| CA (1) | CA2704510A1 (https=) |
| GB (1) | GB0722484D0 (https=) |
| WO (1) | WO2009063222A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20100098772A1 (en) * | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| CA3186189A1 (en) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| GB201017048D0 (en) * | 2010-10-08 | 2010-11-24 | Ucl Business Plc | Composition |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| EP2852383A4 (en) * | 2012-05-21 | 2016-03-16 | Dcb Usa Llc | METHODS OF DRUG TEST USING THE ZEBRAFIC MODEL AND COMPOUNDS TESTED THEREIN |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| EP3142645A4 (en) | 2014-05-15 | 2017-12-27 | Rani Therapeutics, LLC | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016257813B2 (en) * | 2015-05-01 | 2021-05-13 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| AU2016261599B2 (en) * | 2015-05-08 | 2021-08-26 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3442479B1 (en) | 2016-04-20 | 2026-03-04 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3206726A1 (de) * | 1982-02-25 | 1983-09-01 | Merck Patent Gmbh, 6100 Darmstadt | Pharmakadepot |
| DK90883A (da) * | 1982-03-18 | 1983-09-19 | Merck & Co Inc | Beholder til osmotisk afgivelse af et stof eller en stofblanding |
| US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| JPH04504103A (ja) * | 1988-07-01 | 1992-07-23 | ファルマシア・アンド・アップジョン・カンパニー | 植込錠から制御放出される抗生物質塩 |
| GB8827308D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
| US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
| US5114953A (en) * | 1990-11-21 | 1992-05-19 | University Of Florida | Treatment for tissue ulceration |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5817627A (en) * | 1996-06-14 | 1998-10-06 | Theratechnologies Inc. | Long-acting galenical formulation for GRF peptides |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| IL158412A0 (en) * | 2001-04-26 | 2004-05-12 | Bristol Myers Squibb Co | A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load |
| US20030199449A1 (en) * | 2002-04-19 | 2003-10-23 | Tarcha Peter J. | Combination of ablation and controlled drug delivery for the treatment of cancer |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| JP2007523912A (ja) * | 2004-02-26 | 2007-08-23 | アドバンスト アキュラー システムズ リミテッド | 眼病変治療用へパリン |
-
2007
- 2007-11-15 GB GBGB0722484.3A patent/GB0722484D0/en not_active Ceased
-
2008
- 2008-11-17 US US12/743,147 patent/US20100278896A1/en not_active Abandoned
- 2008-11-17 EP EP08850655A patent/EP2219644A2/en not_active Withdrawn
- 2008-11-17 CA CA2704510A patent/CA2704510A1/en not_active Abandoned
- 2008-11-17 JP JP2010533657A patent/JP2011503162A/ja active Pending
- 2008-11-17 CN CN2008801161268A patent/CN102316854A/zh active Pending
- 2008-11-17 WO PCT/GB2008/003851 patent/WO2009063222A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503162A5 (https=) | ||
| Lee et al. | Biodegradable implants for sustained drug release in the eye | |
| WO2009129437A4 (en) | Methods and compositions for treating post-operative pain comprising clonidine | |
| WO2009129509A3 (en) | Methods and compositions for treating post-operative pain comprising a local anesthetic | |
| WO2009129210A4 (en) | Compositions and methods for treating post-operative pain using clonidine and bupivacaine | |
| JP2007535535A5 (https=) | ||
| JPH11507951A (ja) | セレジリン投与による末梢ニューロパシーの予防および治療方法 | |
| US20220072011A1 (en) | Treatments of accumulated fat with deoxycholic acid and salts thereof | |
| JP2018522070A (ja) | 白内障の処置用組成物 | |
| JP2014520893A5 (https=) | ||
| JP2008533140A (ja) | 術後鎮痛剤の低減 | |
| AU2020262932B2 (en) | Intracanalicular hydrogel inserts for the delivery of anesthetics | |
| JP6196704B2 (ja) | 神経因性疾病の治療のための医薬 | |
| JP2020505416A (ja) | リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤 | |
| JP2020505422A (ja) | リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画 | |
| JP2023533774A (ja) | ブプレノルフィンを送達するための親水性分解性マイクロスフェア | |
| AU2006219729A1 (en) | Methods and pharmaceutical compositions for the treatment of neurological damage | |
| WO2020232539A1 (en) | Sustained release local anesthetic hydrogel composition | |
| WO2011028718A1 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| US6518308B2 (en) | Compositions for adhesion prevention | |
| JP2023519090A (ja) | 難聴治療用制御放出型製剤およびその製造方法 | |
| TW201028176A (en) | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye | |
| WO2019172920A1 (en) | Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain | |
| RU2362564C1 (ru) | Способ медикаментозной коррекции 2 стадии желчекаменной болезни у пациентов с описторхозом | |
| WO2024170690A1 (en) | Medical device, kit, method, and anti-inflammatory substance |